Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 35.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 310,650 shares of the company's stock after acquiring an additional 80,536 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.52% of Protagonist Therapeutics worth $11,963,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. Franklin Resources Inc. boosted its stake in shares of Protagonist Therapeutics by 127.2% during the 3rd quarter. Franklin Resources Inc. now owns 81,591 shares of the company's stock worth $3,782,000 after purchasing an additional 45,674 shares during the last quarter. Swedbank AB acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $2,250,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Protagonist Therapeutics by 7.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company's stock worth $25,448,000 after purchasing an additional 39,850 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Protagonist Therapeutics by 3,099.4% during the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after purchasing an additional 310,804 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $861,000. 98.63% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now owns 13,130 shares of the company's stock, valued at $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares of the company's stock, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,776 shares of company stock valued at $3,585,010 over the last 90 days. 5.40% of the stock is owned by corporate insiders.

Protagonist Therapeutics Price Performance

NASDAQ PTGX traded down $0.17 during mid-day trading on Wednesday, hitting $54.35. The company's stock had a trading volume of 1,048,614 shares, compared to its average volume of 740,092. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60. The stock's fifty day simple moving average is $40.25 and its two-hundred day simple moving average is $42.39. The firm has a market capitalization of $3.34 billion, a P/E ratio of 20.43 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The firm had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on PTGX. JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. JMP Securities reiterated a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. BMO Capital Markets increased their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Truist Financial increased their price objective on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a "buy" rating in a report on Tuesday, March 11th. Finally, BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a report on Monday, March 3rd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $62.56.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.